Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
BURLINGTON, Mass., Aug. 01, 2017 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in two investor conferences.
JJ Pellegrino, Chief Financial Officer, will participate in the Needham MedTech One-on-One Conference on Tuesday, August 8, 2017 at One Federal Street in Boston, MA.
George LeMaitre, Chairman & CEO, is scheduled to present at the Canaccord Genuity 37th Annual Growth Conference on Thursday, August 10, 2017 at the Intercontinental Hotel in Boston, MA. The Company’s presentation is scheduled to begin at 9:00 AM EDT.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
Contact: LeMaitre Vascular, Inc. Investor Relations Steven Chehames +1-781-425-1659 [email protected]
